Stay updated on Immunotherapy in Stage IV Melanoma Patients Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy in Stage IV Melanoma Patients Clinical Trial page.

Latest updates to the Immunotherapy in Stage IV Melanoma Patients Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page now states potential funding-related delays and current NIH Clinical Center operating status, and updates the version to v3.2.0, replacing v3.1.0.SummaryDifference3%

- Check35 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check50 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed as a minor UI change.SummaryDifference0.2%

- Check57 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important factors.SummaryDifference0.2%

- Check64 days agoChange DetectedThe web page has been updated to include new drug information related to immunotherapy, specifically for Ipilimumab, Pembrolizumab, and Nivolumab, while removing several previous references to locations and certain medical topics.SummaryDifference4%

- Check78 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to Immunotherapy in Stage IV Melanoma Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy in Stage IV Melanoma Patients Clinical Trial page.